Helena Linardou graduated from the Medical School, Athens University and specialized in Medical Oncology in Athens and London. She studied and developed her research on targeting monoclonal antibodies at the Royal Postgraduate Medical School, Imperial College London, successfully obtaining a PhD in Oncology. During her stay in London, she gained significant experience in medical oncology and produced important research work of international interest, particularly involved in breast, lung and cancer genetics, and in the development of new technologies and molecularly targeted therapies. Returning to Greece she worked at Metropolitan Hospital in Athens, initially as Consultant and from May 2006 as Assistant Director. She also held an Associate Professor position at the University of West Attica. Since September 2018, she is the Director of the 4th Oncology Dept at Metropolitan Hospital, coordinating and conducting large number of clinical studies, and heading the Comprehensive Clinical Trials Center with a specialized clinical trials team. She is the Scientific Chair of the Hellenic Cooperative Oncology Group (HeCOG), and Coordinator of the Lung Cancer Working Group. She is an active member of international scientific societies, ESMO, ASCO, IASLC, AACR, EUSOMA, and currently the Chair of the ESMO W4O Committee and member of ESMO Council as well as elected member of the ESMO Nomination Committee. She is a Mentor of the IASLC Academy and member of the IASLC Education Committee.